Oxford’s PepGen Launches Into DMD With Next-Gen Oligonucleotide Platform

Aims To Challenge Sarepta

Arising from an Oxford and Cambridge university collaboration, the spin-out has selected Duchenne muscular dystrophy as the first target for its peptide platform.

Caroline Godfrey
PepGen's chief executive Caroline Godfrey.

New UK biotech company PepGen has raised $45m in Series A funding and has unveiled Duchenne muscular dystrophy (DMD) as the first target for its next-generation oligonucleotide platform.

Spun out two years ago from Oxford University with funding from Oxford Science Innovation (OSI), PepGen’s financing has been led...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip